Categories: NewsPharmaceutical

Athira Pharma to Participate in Sidoti December Small Cap Investor Conference

Company Presentation to highlight novel therapeutic candidates targeting the HGF neurotrophic system in late-stage clinical development in neurodegenerative diseases, including Alzheimer’s disease

BOTHELL, Wash., Nov. 29, 2023 (GLOBE NEWSWIRE) — Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in the Sidoti December Small Cap Conference, taking place virtually from December 6-7, 2023. Details are as follows:

Sidoti December Small Cap Conference
Format: Company Presentation
Date and Time: Wednesday, December 6, 2023, from 12:15 pm – 12:45 pm EST
Location: Virtual

A live webcast of the presentation can be accessed from the Investors section of the Athira website at https://investors.athira.com/news-and-events/events-and-presentations-investor. An archived replay will be available for at least 30 days following the event.

Athira Pharma will also host virtual one-on-one meetings with investors on Wednesday, December 6 and Thursday, December 7. To register for the conference and schedule a one-on-one meeting, please visit
https://sidoti.com/events.

About Athira Pharma, Inc.
Athira Pharma, Inc., headquartered in the Seattle, Washington area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Athira aims to alter the course of neurological disease by advancing its pipeline of therapeutic candidates targeting the HGF neurotrophic system for Alzheimer’s and Parkinson’s disease, Dementia with Lewy bodies, and amyotrophic lateral sclerosis. For more information, visit www.athira.com. You can also follow Athira on FacebookLinkedIn and @athirapharma on X, formerly known as Twitter, and Instagram.

Investor & Media Contact:

Julie Rathbun
Athira Pharma
Julie.rathbun@athira.com
206-769-9219

Staff

Recent Posts

Teknova Announces Closing of $15.4 Million Private Placement

HOLLISTER, Calif., July 12, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a…

22 hours ago

Faith In Young Champions: Hisense Partners with UEFA Foundation to Bring the Beautiful Game to Hospitalized Children

QINGDAO, China, July 12, 2024 /PRNewswire/ -- During the EURO 2024 tournament, the global home…

1 day ago

JANONE CONFIRMS NAME CHANGE TO ALT5 SIGMA CORPORATION AND NEW TICKER SYMBOL TO ALTS

LAS VEGAS, July 12, 2024 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a multidisciplinary organization with…

1 day ago

Hospital Español Auxilio Mutuo De Puerto Rico, Inc. Reports Network Breach

Important Notice About a Privacy MatterSAN JUAN, PUERTO RICO / ACCESSWIRE / July 12, 2024…

1 day ago

Nano Labs Announces Receipt of Deficiency Letters from Nasdaq

HANGZHOU, China, July 12, 2024 /PRNewswire/ -- Nano Labs Ltd (Nasdaq: NA) ("we," the "Company" or…

2 days ago

Inhance Technologies’ Statement in Response to EPA’s Section 6 Approach on Fluorination of Plastic Containers

HOUSTON, July 12, 2024 /PRNewswire/ -- Inhance Technologies welcomes the opportunity to engage with the…

2 days ago